Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration

British Journal of Ophthalmology

Volumn 95, Issue 3, 2011, Pages 386-390

  Gupta, Bhaskar ^a   Adewoyin, Temilade ^a   Patel, Sheryl Kay ^a   Sivaprasad, Sobha ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPLEGIC AGENT; RANIBIZUMAB; STEROID;

AGED; ARTICLE; CENTRAL MACULA THICKNESS; CONTROLLED STUDY; DISEASE REGISTRY; DOSAGE SCHEDULE COMPARISON; ENDOPHTHALMITIS; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; IRIDOCYCLITIS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA LUTEA; RETINA TEAR; RETREATMENT; RETROSPECTIVE STUDY; SLIT LAMP; STEROID THERAPY; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; UNITED KINGDOM; UVEITIS; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LONDON; MACULAR DEGENERATION; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 79952014297     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2010.179499     Document Type: Article

References (12)

1. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31. (Pubitemid 44511557)
2. Boyer DS, Antoszyk AN, Awh CC, et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114:246-52. (Pubitemid 46172497)
3. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65.
4. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-83.
5. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58.
6. Kirchhof B, Kellner U, Folz FG, et al. visual acuity and central retinal thickness response profiles and treatment patterns in patients with neovascular AMD treated with ranibizumab in the SUSTAIN study. On Behalf of SUSTAIN study group. Poster presentation. Invest Ophthalmol Vis Sci 2009;50:E-Abstract 2366.
7. Neuner-Jehle M, Scassellati-Sforzolini B, Dryja TP, et al. Clinical pharmacogenetic analysis of patients with neovascular AMD treated with ranibizumab in the EXCITE trial. Poster Presentation. Invest Ophthalmol Vis Sci 2009;50:E-Abstract 722.
8. Dadgostar H, Ventura AA, Chung JY, et al. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology 2009;116:1740-7.
9. Michalova K, Wickremasinghe SS, Tan TH, et al. Ranibizumab treatment for neovascular age-related macular degeneration: from randomized trials to clinical practice. Eye (Lond) 2009;23:1633-40.
10. Rothenbuehler SP, Waeber D, Brinkmann CK, et al. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Am J Ophthalmol 2009;147:831-7.
11. Querques G, Azrya S, Martinelli D, et al. Ranibizumab for exudative age-related macular degeneration: 24 months outcomes from a single-centre institutional setting. Br J Ophthalmol 2010;94:292-6.
12. Squirrell DM, Mawer NP, Mody CH, et al. Visual outcome after intravitreal ranibizumab for wet age-related macular degeneration: a comparison between best-corrected visual acuity and microperimetry. Retina 2010;30:436-42.